Company intelligence / Profile preview

ConSynance Therapeutics

Rensselaer, New York, United Statesconsynance.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CSTI-500 has completed three Phase 1 clinical trials, including two in healthy volunteers and one in PWS patients. The drug showed a similar efficacy profile in all three trials with no reported severe adverse events. PET imaging has revealed CSTI-500's brain target engagement in healthy volunteers. The FDA has granted Rare Pediatric Disease Designation (RPDD) to CSTI-500 for the treatment of PWS in children and adolescents.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CSTI-500

Partnerships

Harmony Biosciences (developing HBS-102)Member of the PWS Clinical Trial Consortium

Beyond the preview

Go deeper on ConSynance Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ConSynance Therapeutics.

Explore the full profile